RT Journal Article
SR Electronic
A1 Nichols, Emma Hitt
T1 RPC1063 Safe and Effective in RRMS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 29
SP 12
OP 13
DO 10.1177/155989771429009
UL http://mdc.sagepub.com/content/14/29/12.abstract
AB Treatment with the sphingosine 1-phosphate (S1P) receptor modulator, RPC1063, resulted in a substantial decrease in gadolinium-enhancing (Gd+) lesions and the number of new or enlarging T2 lesions in patients with relapsing-remitting multiple sclerosis (RRMS). This article presents data from the Efficacy and Safety Study of RPC1063 in Relapsing Multiple Sclerosis Patients trial [Radiance Study; NCT01628393].